Long-form analysis at the intersection of AI and life sciences — all spells, sorted by time.
Telomeres are usually cast as the cell's countdown timer that hits zero and you age. But two studies show they manage far more than time: shorten them, and immune cells' mitochondria misfire, inflammation ignites, and cognition takes a causally-linked hit. Telomeres, it turns out, move both inflammation and brainpower.
You took NMN for three months and still look the same in the mirror. Why? Three landmark studies piece together how NAD⁺ collapses with age: how cells fake hypoxia, who eats your supplements, and whether topping NAD⁺ back up can truly rejuvenate old cells.
We've heard plenty of mouse stories about NAD⁺ falling with age. Three studies finally move it onto real humans: a tube of blood, a brain scan, and a randomized double-blind trial each confirm NAD⁺ truly declines in us, while honestly flagging that the clinical payoff is still unsettled.
A single AI Agent is reliable. But your cognitive bandwidth caps at 5 parallel threads. Skill Graphs 2.0 introduces a three-layer architecture — atoms (deterministic), molecules (fixed sequence), compounds (strategic autonomy) — turning 5 compound-level tasks into 500 work units. This article breaks down the framework, practical principles, and known limitations.
Anthropic, the UK AI Safety Institute, and the Alan Turing Institute have demonstrated that inserting just 250 carefully crafted documents into training data can plant a permanent backdoor in LLMs ranging from 600M to 13B parameters. Bigger models and more data do not dilute the poison.
In 2026, NMN entered its first clinical trial for autoimmune disease and appeared in Nature Medicine. Combined with new evidence on T cell senescence reversal and exercise-driven SIRT1 activation, three studies map NAD+ as an immune calibrator.